Lucinda Harris, MD
Gastroenterology · Scottsdale, AZNPI 1891778643
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $29,525 of the $37,556 with a category attached, or 78.6%. 11 manufacturers reported payments, led by Salix Pharmaceuticals, A Division Of Bausch Health US, LLC at 30.6% of the total. Reporting peaked in 2021 at $12,935 and has fallen 95.0% since, to $645 in 2025. Among gastroenterology clinicians in AZ with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 65 payments — averaging $577.78 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$11K
- AbbVie$11K
- Ardelyx, Inc.$9K
- Alnylam Pharmaceuticals Inc.$5K
- Mahana Therapeutics, Inc.$1K
- QOL Medical, LLC$339
- plus $419 from 5 others
Across 70 payments — averaging $4722.99 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Takeda Pharmaceuticals U.S.A., Inc.$316K
- AbbVie$14K
What the payments were for
- Consulting fees$29,52579%
- Speaking & faculty fees$3,2259%
- Travel & lodging$180%
- Food & beverage$4,78813%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 33 | $11,494 |
| AbbVie | 5 | $10,792 |
| Ardelyx, Inc. | 14 | $8,689 |
| Alnylam Pharmaceuticals Inc. | 4 | $4,818 |
| Mahana Therapeutics, Inc. | 2 | $1,005 |
| QOL Medical, LLC | 2 | $339 |
| Evoendo, Inc | 1 | $131 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $111 |
| Cumberland Pharmaceuticals, Inc. | 1 | $99 |
| Anx Robotica Corp | 1 | $47 |
| Shire North American Group Inc | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$37,556 in reported general payments places this provider in the 90th percentile of 355 gastroenterology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XifaxanRifaximin | 14 | $49,635 |
| MotegrityPrucalopride Succinate | 49 | $41,629 |
| LinzessLinaclotide | 36 | $31,915 |
| Pantoprazole Sodium | 94 | $3,364 |
| Pyridostigmine Bromide | 23 | $1,954 |
| Prochlorperazine | 12 | $1,521 |
| Doxycycline Monohydrate | 23 | $1,312 |
| Diphenhydramine Hcl | 15 | $1,261 |
| ErythromycinErythromycin Base | 16 | $1,213 |
| Ondansetron HclOndansetron Hcl/Pf | 15 | $1,130 |
| Lansoprazole | 17 | $855 |
| Colestipol Hcl | 12 | $824 |
| Budesonide DrBudesonide | 18 | $761 |
| Omeprazole | 47 | $589 |
| FamotidineFamotidine/Pf | 15 | $461 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan | $11,494 | $49,63514 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Motegrity | $111 | $41,62949 claims |
| AbbVieLinzess | $10,792 | $31,91536 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 355 gastroenterology providers in Arizona.
Other gastroenterology in Scottsdale
- Daniel MelineScottsdale$795K
- David FleischerScottsdale$410K
- Pankaj PasrichaScottsdale$304K
- Norio FukamiScottsdale$215K
- Toufic KachaamyScottsdale$210K
- Christina HaScottsdale$198K
- Woong KimScottsdale$138K
- Adam HarrisScottsdale$127K
- Anil SeetharamScottsdale$111K
- Amar ThosaniScottsdale$97K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.